Enhanced biological activity of 1α,25-dihydroxy-20-epi-vitamin D3, the C-20 epimer of 1α,25-dihydroxyvitamin D3, is in part due to its metabolism into stable intermediary metabolites with significant biological activity

Journal of Steroid Biochemistry and Molecular Biology

Volumn 71, Issue 3-4, 1999, Pages 111-121

  Siu Caldera, M L ^a   Sekimoto, H ^a   Peleg, S ^b   Nguyen, C ^b   Kissmeyer, A M ^c   Binderup, L ^c   Weiskopf, A ^d   Vouros, P ^d   Uskokovic M R ^e   Reddy, G S ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LEO PHARMA A S   (Denmark)

^d NORTHEASTERN UNIVERSITY   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG STRUCTURE; KIDNEY PERFUSION; MALE; NONHUMAN; RAT; TISSUE METABOLISM; VITAMIN METABOLISM;

ANIMALS; CALCITRIOL; GENES, REPORTER; HUMANS; KIDNEY; LIGANDS; MALE; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITRIOL; STEREOISOMERISM; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0033406692     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(99)00130-2     Document Type: Article

References (26)

1. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 16:1995;200-257.
2. Jung S.J., Lee Y.Y., Pakkala S., de Vos S., Elstner E., Norman A.W., Green J., Uskokovic M.R., Koeffler H.P. 1α,25(OH)2-16-ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia. Leuk. Res. 18:1994;453-463.
3. Reddy G.S., Clark J.W., Tserng K.-Y., Uskokovic M.R., McLane J.A. Metabolism of 1α,25(OH)2-16-ene-D3 in kidney: Influence of structural modification of D-ring on side chain metabolism. Bioorg. Med. Chem. Lett. 3:1993;1879-1884.
4. Lemire J.M., Archer D.C., Reddy G.S. 1α,25-dihydroxy-24oxo-16ene-vitamin D3, a renal metabolite of the vitamin D analog 1α,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology. 135:1994;2818-2821.
5. Siu-Caldera M.-L., Clark J.W., Santos-Moore A., Peleg S., Liu Y.-Y., Uskokovic M.R., Sharma S., Reddy G.S. 1α,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1α,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating equipotent to its parent in modulating growth and differentiation of human leukemic cells. J. Steroid Biochem. Molec. Biol. 59:1996;405-412.
6. Binderup L., Latini S., Binderup E., Bretting C., Calverley M., Hansen K. 20-epi-vitamin D3 analogues: A novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. 42:1991;1569-1575.
7. Elstner E., Lee Y.Y., Hashiya M., Pakkala S., Binderup L., Norman A.W., Okamura W.H., Koeffler H.P. 1α,25-dihydroxy-20-epi-vitamin D3: An extraordinary potent inhibitor of leukemic cell growth in vitro. Blood. 84:1994;1960-1967.
8. Elstner E., Heber D., Koeffler H.P. 20-epi-vitamin D3 analogs. Potent modulators of proliferation and differentiation of breast cancer cell lines in vitro. Adv. Exp. Med. Biol. 399:1996;53-70.
9. Gniadecki R. Effects of 1α,25-dihydroxyvitamin D3 and its 20-epi analogues (MC 1288, MC 1301, KH 1060), on clonal keratinocyte growth: evidence for differentiation of keratinocyte stem cells and analysis of the modulatory effects of cytokines. Br. J. Pharmacol. 120:1997;1119-1127.
10. Dilworth F.J., Calverley M.J., Makin H.L.J., Jones G. Increased biological activity of 20-epi-1,25-dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding. Biochem. Pharmacol. 47:1994;987-993.
11. Kissmeyer A.-M., Mathiasen I.S., Latini S., Binderup L. Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP). Endocrine. 3:1995;263-266.
12. Peleg S., Sastry M., Collins E.D., Bishop J.E., Norman A.W. Distinct conformational changes induced by 20-epi analogues of 1α,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J. Biol. Chem. 270:1995;10551-10558.
13. Nayeri S., Mathiasen I.S., Binderup L., Carlberg C. High-affinity nuclear receptor binding of 20-epi analogues of 1,25-dihydroxyvitamin D3 correlates well with gene activation. J. Cell. Biochem. 62:1996;325-333.
14. van den Bemd G.C.M., Pols H.A.P., Birkenhager J.C., van Leeuwen J.P.T.M. Conformational change and enhanced stabilization of the vitamin D receptor by the 1α-,25-dihydroxyvitamin D3 analog KH1060. Proc. Natl. Acad. Sci. USA. 93:1996;10685-10690.
15. Liu Y.-Y., Collins E.D., Norman A.W., Peleg S. Differential interaction of 1α,25-dihydroxyvitamin D3 analogues and their 20-epi homologues with the vitamin D receptor. J. Biol. Chem. 272:1997;3336-3345.
16. Reddy G.S., Jones G., Kooh S.W., Fraser D. Inhibition of 25-hydroxyvitamin D3-1-hydroxylase by chronic metabolic acidosis. Am. J. Physiol. 243:1982;E265-E271.
17. Reddy G.S., Tserng K.-Y., Thomas B.R., Dayal R., Norman A.W. Isolation and identification of 1,23-dihydroxy-24,25,26,27-tetranorvitamin D3, a new metabolite of 1,25-dihydroxyvitamin D3 produced in rat kidney. Biochemistry. 26:1987;324-331.
18. Peleg S., Nguyen C., Woodard B.T., Lee J.K., Posner G.H. Differential use of transcription activation function 2 domain of the vitamin D receptor by 1,25-dihydroxyvitamin D3 and its A ring-modified analogs. Mol. Endocrinol. 12:1998;525-535.
19. Ozono K., Liao S.A., Kerner S.A., Scott R.A., Pike J.W. The vitamin D-responsive element in the human osteocalcin gene: association with a nuclear proto-oncogene enhancer. J. Biol. Chem. 265:1990;21881-21888.
20. Lopata M.A., Cleveland D.W., Sollner-Webb B. High level transient expression of a chloramphenicol acetyl transferase gene by DEAE-dextran mediated DNA transfection coupled with a dimethyl sulfoxide or glycerol shock treatment. Nucleic Acids Res. 12:1984;5707-5717.
21. Siu-Caldera M.-L., Zou L., Ehrlich M.G., Schwartz E.R., Ishizuka S., Reddy G.S. Human osteoblasts in culture metabolize both 1α,25-dihydroxyvitamin D3 and its precursor 25-hydroxyvitamin D3 into their respective lactones. Endocrinology. 136:1995;4195-4203.
22. Campbell M.J., Reddy G.S., Koeffler H.P. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J. Cell. Biochem. 66:1997;413-425.
23. Kiriyama T., Okamoto S., Ejima E., Kurihara N., Hakeda Y., Ito N., Izumi M., Kumegawa M., Nagataki S. Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. Endocrinology. 128:1991;81-86.
24. Honda A., Nakashima N., Mori Y., Katsumata T., Ishizuka S. Effects of vitamin D-binding proteins on HL-60 cell differentiation induced by 26,26,26,27,27,27-hexafluoro-1α,25-dihydroxyvitamin D3. J. Steroid Biochem. Molec. Biol. 41:1992;109-112.
25. Harada M., Miyahara T., Kajita-Kondo S., Kozakai A., Higuchi S., Otomo S., Kozuka H. Differences in metabolism between 26,26,26,27,27,27-hexafluoro-1α,25-dihydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 in cultured neonatal mouse calvaria. Res. Commun. Molec. Pathol. Pharma. 86:1994;183-193.
26. Dilworth F.J., Williams G.R., Kissmeyer A.-M., Nielsen J.L., Binderup E., Calverley M.J., Makin H.L.J., Jones G. The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology. 138:1997;5485-5496.